Pharma-Bio Serv, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023
September 14, 2023 at 04:17 pm EDT
Share
Pharma-Bio Serv, Inc. reported earnings results for the third quarter and nine months ended July 31, 2023. For the third quarter, the company reported sales was USD 4.58 million compared to USD 4.77 million a year ago. Net income was USD 0.526242 million compared to USD 0.288034 million a year ago. Basic earnings per share from continuing operations was USD 0.023 compared to USD 0.013 a year ago. Diluted earnings per share from continuing operations was USD 0.023 compared to USD 0.013 a year ago.
For the nine months, sales was USD 13.38 million compared to USD 14.76 million a year ago. Net income was USD 1.36 million compared to USD 0.833305 million a year ago. Basic earnings per share from continuing operations was USD 0.059 compared to USD 0.036 a year ago. Diluted earnings per share from continuing operations was USD 0.059 compared to USD 0.036 a year ago.
Pharma-Bio Serv, Inc. is a compliance and technology transfer services consulting company. The Company operates through four segments: Puerto Rico technical compliance consulting, United States technical compliance consulting, Europe technical compliance consulting, and Puerto Rico microbiological and chemical laboratory testing division (Lab). The Company provides a range of compliance-related consulting services. The Company provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. The Company's technical consulting services include regulatory compliance, validation, technology transfer, engineering, project management and process support. The Company markets its services to pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies in Puerto Rico, the United States, Europe and Brazil.
PHARMA-BIO SERV, INC. 
